# The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

> **NCT05374291** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **University Medical Center Groningen** · enrollment: 1750 (estimated)

## Conditions studied

- Kidney Disease, Chronic
- Renal Transplant Failure
- Heart Failure
- Kidney Failure
- Death

## Interventions

- **DRUG:** Dapagliflozin 10 mg/day (oral)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05374291
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-11-08
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 1750 (ESTIMATED)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05374291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05374291, "The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05374291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*